@misc{Gronostaj_Katarzyna_The_2020, author={Gronostaj, Katarzyna}, address={Kraków}, howpublished={online}, year={2020}, school={Rada Dyscypliny Nauki medyczne}, language={pol; eng}, abstract={The survival benefit of neoadjuvant chemotherapy (NAC) in the muscle invasive bladder cancer (MIBC) treatment is well established, nevertheless NAC has not been widely used in Poland. The study was conducted in three stages in the Department of Urology, Jagiellonian Uniwersity Medical College. The aim of the first paper was to investigate the association between NAC utilization and survival, postoperative mortality and morbidity in patients with MIBC who underwent radical cystectomy (RC). In the second study the prognostic value of tumor regression grade (TRG) and TRG integrated with TNM was investigated. The aim of third paper was to analyze temporal changes in NAC utilization among MIBC patients who underwent RC. In the first study the overall survival (OS) and recurrence free survival (RFS), 90-days mortality and morbidity rates were compared between patients who underwent NAC and RC and those, who underwent only RC (Dec. 2012- Dec. 2017). In the second paper among patients who underwent complete NAC and RC (period as above) TRGs were assesed and OS and RFS were compared according to TRG and TRG integrated with TNM. In the third study the percentages of NAC utilization were assesed between 2013 and 2018 among MIBC patients who underwent RC. The use of NAC followed by RC in MIBC patients was associated with a better prognosis (OS, RFS) than RC alone, 90-days postoperati}, abstract={ve morbidity and mortality rates were similar in both groups. TRG and TRG integrated with TNM showed prognostic value in patients with MIBC who underwent NAC and RC. There was an increasing utilization of NAC between 2013 and 2018 amongst MIBC patients who underwent RC.}, title={The impact of neoadjuvant chemotherapy on treatment outcomes of muscle invasive bladder cancer patients who underwent radical cystectomy}, type={Praca doktorska}, keywords={muscle invasive bladder cancer, neoadjuvant chemotherapy, tumor regression grade}, }